ALMOND THERAPY: TARGETING THE AMYGDALA

Welcome to the Brand page for “ALMOND THERAPY: TARGETING THE AMYGDALA”, which is offered here for Provision of education in the nature of providing courses of instruction and training in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; provision of education in the nature of providing courses of instruction and training in the field of psychedelic medicines;compilation of medical data for financial purposes relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes;compilation for business purposes and processing of medical data relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes;psychotherapy services; mental health therapy for the treatment of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; provision of information to others in the field of mental health; clinical mental health counselling services;therapy;medical and scientific research and development in the field of psychedelics; medical and scientific research in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; laboratory research in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; providing temporary use of online, non-downloadable computer software for providing therapy services in the nature of scheduling and facilitating internet-based patient and medical provider meetings to individuals in the field of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes; compilation of medical data for research purposes relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, covid-19 symptoms and syndromes;.

Its status is currently believed to be active. Its class is unavailable. “ALMOND THERAPY: TARGETING THE AMYGDALA” is believed to be currently owned by “PsiloTec Health Solutions Inc.”